Temozolomide plus M1774 for advanced metastatic cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, and you have an advanced cancer that has spread (metastatic).
- Your cancer must be confirmed by lab testing (tumor tissue or cells).
- You must be well enough to do daily activities (ECOG 0–2 or equivalent).
- Your blood counts and organ labs must be high enough (examples: hemoglobin ≥10, adequate white cells/platelets, kidney function ok, and liver enzymes within limits).
- Your cancer results must match the study plan, which often requires a biopsy-accessible tumor and specific genetic/molecular marker results (like MGMT status, and for colorectal cancer the mismatch repair status).
- You must be able to take study pills by mouth, agree to birth control rules (and avoid pregnancy), and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This study tests a chemotherapy drug called temozolomide for people with advanced melanoma (skin cancer) that has a specific genetic change called BAP1. The drug may help shrink tumors or slow the cancer's growth, especially for people who have already tried other treatments.
This trial tests an experimental pill for several advanced cancers, including soft tissue sarcoma, endometrial cancer, low-grade ovarian cancer, and glioblastoma. The goal is to see how safe the drug is and if it can slow down or shrink tumors.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests whether adding cannabinoid medicine to temozolomide helps people whose glioblastoma (GBM) has returned. It compares temozolomide plus cannabinoids versus temozolomide alone, using blinded treatment so neither you nor the team knows which option you get.
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.